CAR-T cell therapy for autoimmune diseases that haven't responded to standard treatments
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with one of these: multiple sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis, systemic lupus erythematosus, systemic sclerosis, or immune-mediated necrotizing myopathy for at least 6 months.
- Standard treatments for your condition have not worked well enough.
- You have adequate bone marrow, blood clotting, heart, lung, liver, and kidney function.
- You do not have active infections like hepatitis B or C, HIV, or other listed viruses.
- You have not had prior CAR-T cell therapy or a transplant of organs or bone marrow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.